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Abstract
Aim: To compare the effects of a glucagon-like peptide-1 receptor agonist and a
dipeptidyl peptidase-4 inhibitor on magnetic resonance imaging-derived measures of
cardiovascular function.
Materials and methods: In a prospective, randomized, open-label, blinded endpoint trial
liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non-insulin
treated young (aged 18-50 years) adults with obesity and type 2 diabetes. The primary
outcome was difference in circumferential peak early diastolic strain rate change
(PEDSR), a biomarker of cardiac diastolic dysfunction 26 weeks after randomization.
Secondary outcomes included other indices of cardiac structure and function, HbA1c
and body weight.
Results: Seventy-six participants were randomized (54% female, mean ± SD age 44 ±
6 years, diabetes duration 4.4 years, body mass index 35.3 ± 6.1 kg m−2), of whom
65% had ≥1 cardiovascular risk factor. Sixty-one participants had primary outcome data
available. There were no statistically significant between-group differences (intention-
to-treat; mean [95% confidence interval]) in PEDSR change (−0.01 [−0.07, +0.06] s−1),
left ventricular ejection fraction (−1.98 [−4.90, +0.94]%), left ventricular mass (+1.14
[−5.23, +7.50] g) or aortic distensibility (−0.35 [−0.98, +0.28] mmHg−1 × 10−3) after
26 weeks. Reductions in HbA1c (−4.57 [−9.10, −0.37] mmol mol−1) and body weight
(−3.88 [−5.74, −2.01] kg) were greater with liraglutide.
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Conclusion: There were no differences in cardiovascular structure or function after
short-term use of liraglutide and sitagliptin in younger adults with obesity and type
2 diabetes. Longer studies in patients with more severe cardiac dysfunction may be
necessary before definitive conclusions can be made about putative pleiotropic
properties of incretin-based therapies.
K E YWORD S
cardiac magnetic resonance, diastolic dysfunction, liraglutide, obesity, peak early
diastolic strain rate, randomized controlled trial, sitagliptin, type 2 diabetes,
young adults
1 | INTRODUCTION
Heart failure is a leading cause of death and disability in people with dia-
betes.1 Drugs commonly used to control glucose appear to have differ-
ing effects on this important patient-centred outcome. Sodium-glucose
co-transporter-2 (SGLT-2) inhibitors reduce all-cause mortality and heart
failure hospitalization through mechanisms believed to be independent
of their capacity to lower blood glucose.2 The impact (if any) of pharma-
cotherapy directly or indirectly activating the glucagon-like peptide-1
(GLP-1) receptor is less certain.3 In 2013, concern was raised after the
dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin was associated with
increased hospitalization for congestive cardiac failure in a secondary
endpoint analysis of the Savor-Timi 53 trial.4 This finding generated the
hypothesis that incretin-based treatments exert disparate actions on car-
diac function. More recently, a number of studies have explored the
actions of both GLP-1 receptor agonists and DPP-4 inhibitors on mostly
echocardiographic estimates of cardiac function in patients with type
2 diabetes and co-existent heart failure.5-10 Depending on the popula-
tion studied, these have reported little or no effect on left ventricular
ejection fraction (LVEF) and are consistent with the generally neutral
findings of heart failure hospitalization endpoint analyses of more recent
major cardiovascular outcome trials.11-19
To our knowledge there has been only one randomized study
exploring the effects of incretins on diabetes-related measures of
cardiac dysfunction using cardiac magnetic resonance (CMR) imaging
and none directly comparing a GLP-1 receptor agonist and DPP-4
inhibitor. CMR imaging is the gold standard non-invasive technique
for the assessment of cardiac structure and function.20
We therefore aimed to compare the GLP-1 receptor agonist
liraglutide with the DPP-4 inhibitor sitagliptin using change in CMR
imaging-derived subclinical diastolic dysfunction as the primary out-
come measure in younger asymptomatic adults with type 2 diabetes
who have a significant lifetime risk of developing heart failure.21
2 | METHODS
2.1 | Trial design and oversight
The effects of Liraglutide in Young adults with type 2 DIAbetes (LYDIA)
study was a 26-week, single-centre, prospective, randomized, open-label,
blinded endpoint active comparator trial. The rationale and detailed
design of the study have been reported previously (Clinical trials.gov reg-
istration NCT02043054, EudraCT 2012-002422-78).22 LYDIA was spe-
cifically designed to assess the relative effects of two drugs targeting the
incretin pathway on a CMR imaging-derived biomarker of diastolic func-
tion, circumferential peak early diastolic strain rate (PEDSR). In a pilot trial
conducted at the University of Leicester, excellent test-retest reproduc-
ibility for PEDSR was obtained and this measurement was significantly
decreased in a cross-sectional comparison of younger adults with type
2 diabetes and healthy lean controls.23 Consenting, eligible participants
with type 2 diabetes were randomized 1:1 following baseline measure-
ments to either liraglutide (Victoza), titrated to a maximum dose of
1.8 mg and self-administered via a once-daily subcutaneous injec-
tion, or to an active comparator agent, sitagliptin (Januvia) 100 mg,
given as a once-daily oral tablet. The primary outcome was change
in PEDSR from baseline to 26 weeks. The study was approved by
the West Midlands NHS Research Ethics Committee and the Medi-
cine and Healthcare products Regulatory Agency, conducted in
accordance with good clinical practice guidelines and sponsored by
the University of Leicester. This was a single-centre study, man-
aged by a UK Clinical Research Collaboration-accredited clinical tri-
als unit. The funder (NovoNordisk) had no role in operational
aspects, recruitment, data analysis or interpretation.
2.2 | Study population
Eligible participants aged 18-50 years (upper limit revised to 60 years
of age in 2017) were recruited from primary and secondary care dia-
betes clinics. Inclusion criteria were obesity (body mass index [BMI]
≥30 kg m−2 or ≥27 kg m−2 if of South Asian ethnicity) and type 2 dia-
betes treated with oral glucose-lowering agents (metformin and/or
any sulphonylurea). Patients prescribed insulin, SGLT-2 inhibitor,
GLP-1 receptor agonist or DPP-4 inhibitor therapies were excluded.
2.3 | Interventions
Randomization was concealed via an independent online assignment
system after consent and baseline assessments. Liraglutide was
administered via manufacturer-supplied and labelled 3 mL prefilled
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pens (Victoza 6 mg mL−1) at a starting dose of 0.6 mg daily. Weekly
0.6 mg incremental dose escalation then followed as per protocol and
at the investigator's discretion. Sitagliptin 100 mg daily was obtained
from the manufacturer and both drugs were dispensed by the hospital
clinical trial pharmacy. There was no titration protocol for the active
comparator. Glycaemic control was managed in accordance with
national clinical practice guidance.24 The dose of preprescribed sul-
phonylurea treatment was halved if either baseline HbA1c was less than
58 mmol mol−1 (7.0%) or any episodes of severe hypoglycaemia were
reported during the trial. ‘Rescue therapy’, defined as the addition of
non-incretin-based medication, was considered if fasting plasma glucose
exceeded 11.0 mmol L−1 at visit 4 (12 weeks into the study).
2.4 | Measurements
2.4.1 | CMR image acquisition
CMR imaging was performed using a 1.5 T scanner (Siemens Avanto or
Aera, Erlangen, Germany) with retrospective electrocardiographic gating
and an 18-channel phased-array cardiac receiver coil. The protocol has
been outlined previously.25 In brief, after localizers, steady-state free pre-
cession cine images were acquired in four-, three- and two-chamber
views. Perfusion images were then acquired after vasodilatory stress
with adenosine (140 μg kg−1 min−1, infused intravenously for
3-5 minutes). At peak stress, a gadolinium-based contrast agent
(gadopentetate dimeglumine, Magnevist, Bayer HealthCare LLC, Ger-
many) was injected (0.04 mmol kg−1), followed by a 20 mL bolus of nor-
mal saline, at a rate of 5 mL s−1, and perfusion images were acquired
using a saturation recovery gradient echo pulse sequence for three slices
(base, mid and apex). Rest perfusion images were acquired ~ 10 minutes
after stress with a further 0.04 mmol kg−1 contrast. In between rest and
stress imaging, a stack of short-axis slices was obtained using cine images
to obtain coverage of the entire left ventricle. Following stress imaging, a
cine image of the ascending aorta at pulmonary artery bifurcation with
simultaneous blood pressure measurement was obtained to calculate
aortic distensibility (AD).
2.4.2 | CMR image analysis
All CMR images were analysed offline blinded to all patient details includ-
ing treatment allocation and study timing. Cardiac chamber volumes, func-
tion and strain were assessed by a single experienced observer (GSG)
using cmr42 version 5 (Circle Cardiovascular Imaging, Calgary, Alberta,
Canada).25 Quantitative myocardial perfusion analysis was performed
using signal versus time curves from the myocardium and blood pool,
converted to contrast agent concentration curves assuming a linear signal
response to contrast agent as previously described.26 Myocardial blood
flow (MBF) valueswere estimated using Fermi-constrained deconvolution.
The precontrast baseline signal, end of first-pass time point, and the
bolus arrival time delay between the blood pool and myocardial curves
were calculated using previously described automatedmethods.
2.4.3 | Anthropometric and laboratory
biochemistry
HbA1c was measured via high-performance liquid chromatography
using standardized procedures within the pathology laboratories of
University Hospitals of Leicester NHS Trust. Serum lipids and
creatinine-derived estimated glomerular filtration rate were estimated
using standard enzymatic techniques (ADVIA System, Bayer, NY). All
analyses were undertaken by individuals blinded to the experimental
condition.
Weight was measured to the nearest 0.1 kg using standard
weighing scales. Height was measured to the nearest millimetre using
a stadiometer. Blood pressure and heart rate were measured using
standard operating procedures and equipment (sphygmomanometer
and brachial inflation cuff HEM-7200 M3, Omron Healthcare, Kyoto,
Japan).
2.4.4 | Cardiorespiratory fitness
Participants underwent a maximal incremental exercise test on a
stationary electromagnetically braked cycle ergometer. Throughout
the test, expired gases were sampled continuously and analysed
using indirect calorimetry (Cortex 3B, Cortex Biophysik, Leipzig,
Germany) to determine maximal oxygen consumption (VO2 max),
the gold standard technique for assessment of cardiovascular
fitness.
2.5 | Outcomes
The primary outcome was between-arm difference in circumfer-
ential PEDSR at 26 weeks. This measure declines with early
diastolic dysfunction and typifies diabetic heart disease. It was
chosen based on our previously published data in young people
with type 2 diabetes.27,28 Secondary outcomes were other
CMR imaging-derived measures of left ventricular strain (longitu-
dinal PEDSR, global longitudinal/circumferential strain [LVGLS/
LVGCS]), geometry (left ventricular end diastolic mass index
[LVMI], end-systolic and end-diastolic volume indices [LVESVI
and LVEDVI, respectively]) and function (LVEF), together with
measures of vascular structural integrity, AD, MBF and myocardial
perfusion reserve (MPR). Secondary cardiometabolic outcomes
included HbA1c, plasma lipids (total, LDL- and HDL-cholesterol
and triglycerides), standard plasma liver and renal function, bra-
chial blood pressure and pulse rate, VO2 max and anthropometrics
(body weight, BMI).
2.6 | Statistical analysis and power calculation
This study was designed to assess whether liraglutide was superior to
sitagliptin at producing an increase in PEDSR of more than 0.2 s−1
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after 26 weeks of treatment. A difference of 0.2 s−1 is equivalent to
the difference between patients with diabetes and non-diabetic obese
controls observed previously,27,28 and is therefore likely to be clini-
cally meaningful. To detect this treatment difference of 0.2 s−1,
72 participants (36 per group) were required to complete the trial
(80% power, two-sided alpha = 0.05), assuming a standard deviation
of 0.3 s−1 in circumferential PEDSR.27,28 Baseline characteristics were
compared by group. Generalized linear models were used to generate
treatment effects for the primary and secondary outcomes
adjusted for baseline values along with age, gender, baseline
HbA1c and baseline weight, with results presented as mean
between group differences (liraglutide minus sitagliptin) with 95%
confidence intervals. The primary analysis was conducted on a
complete case basis using intention-to-treat principles. An addi-
tional sensitivity analysis was conducted for the primary outcome
where missing data were replaced with multiple imputations across
20 datasets. Missing data were imputed using the auto imputations
command in SPSS conditional on the following variables: age, gen-
der, blood pressure and BMI. All statistical tests were two-sided
and P <0.05 was considered statistically significant. Data were
analysed using SPSS version 26.
3 | RESULTS
3.1 | Participants and interventions
Between 2 January 2014 (first person first visit) and 13 September
2018 (last person last visit), 230 people with type 2 diabetes who
met the initial age criteria were screened for eligibility. A total of
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76 people were enrolled and randomly assigned to either liraglutide
or sitagliptin. All participants received at least one dose of study
medication. A total of 64 participants completed the study, for
whom primary outcome data were available for 61 CMR imaging
scans. The flow of participants through the trial is shown in
Figure 1.
Characteristics of the study groups were balanced at baseline
(Table 1). The mean age (± SD) of the combined population was
44 (± 6) years. A total of 54% were female and the mean duration of
diabetes was 4.4 years. There was no significant difference in baseline
characteristics between participants completing (n = 64) and not com-
pleting the study (n = 12) (data not shown).
3.2 | Effects on cardiac structure and function
Both groups showed a reduction in diastolic function (circumferential
PEDSR) from baseline of −0.06 (−0.10, −0.01) and −0.05 (−0.10,
TABLE 1 Baseline characteristics Liraglutide Sitagliptin
n n
Age (years) 38 43.4 (7.0) 38 44.8 (5.9)
Female, n (%) 38 18 (47.4) 38 23 (60.5)
Duration of diabetes (years) 38 4.5 (4.5) 38 4.4 (4.4)
Current smoker, n (%) 38 11 (29.0) 38 8 (21.1)
Weight (kg) 38 100.8 (18.8) 38 100.7 (21.1)
Body mass index (kg m−2) 38 35.7 (7.0) 38 34.9 (5.3)
Systolic blood pressure (mmHg) 38 129 (11.9) 38 128 (15.6)
Diastolic blood pressure (mmHg) 38 86 (9.0) 38 85 (9.8)
Heart rate (min−1) 38 81.0 (11.1) 38 76.5 (11.9)
HbA1c (%) 38 7.5 (0.8) 38 7.6 (0.8)
HbA1c (mmol mol−1) 38 58.4 (9.3) 38 59.1 (9.1)
Total cholesterol (mmol L−1) 38 4.7 (1.2) 38 4.6 (0.9)
LDL-C (mmol L−1) 36 2.3 (0.8) 36 2.4 (0.6)
HDL-C (mmol L−1) 38 1.1 (0.2) 37 1.2 (0.3)
Triglycerides (mmol L−1) 38 2.6 (1.5) 38 2.4 (1.7)
Alanine transaminase (IU L−1) 38 39.6 (21.8) 38 33.1 (14.7)
eGFR (mL min−1) 38 87.6 (4.6) 38 89.1 (3.3)
VO2max (mL kg
−1 min−1) 32 23.7 (6.1) 30 23.5 (5.0)
CMR imaging measures
PEDSR (s−1) circumferential 34 1.1 (0.3) 35 1.0 (0.3)
PEDSR (s−1) longitudinal 34 0.9 (0.2) 35 0.9 (0.2)
LVGCS (%) 34 −19.0 (3.3) 35 −19.4 (2.8)
LVGLS (%) 34 −15.8 (2.8) 35 −16.4 (2.3)
LVEDVI (mL m−2) 34 69.9 (15.0) 35 70.8 (13.9)
LVEF (%) 34 64.5 (10.4) 35 65.6 (6.2)
LVM (g) 34 120.6 (28.7) 35 118.0 (27.8)
LVMI (g m−2) 34 55.3 (10.3) 35 54.5 (8.7)
LV peak filling rate (mL s−1) 34 555.9 (109.4) 34 547.7 (108.0)
LVM/V (g mL−1) 34 0.80 (0.13) 35 0.79 (0.14)
Max. LA vol. (mL) 32 68.3 (21.0) 35 73.7 (20.1)
Global stress MBF (mL min−1 g−1) 30 3.7 (1.2) 34 3.6 (0.9)
Global rest MBF (mL min g−1) 30 1.4 (0.5) 33 1.4 (0.5)
MPR 30 3.0 (1.2) 33 2.9 (1.0)
Mean AD (mmHg−1 × 10−3) 32 4.1 (1.3) 26 4.2 (1.9)
Abbreviations: AD, aortic distensibility; CMR, cardiac magnetic resonance imaging measures; eGFR,
estimated glomerular filtration rate; LV, left ventricular; LVEDVI, left ventricular end-diastolic volume
index; LVEF, left ventricular ejection fraction; LVGCS, left ventricular global circumferential strain;
LVGLS, left ventricular global longitudinal strain; LVM, left ventricular mass; LVMI, left ventricular mass
index; LVM/V, left ventricular mass/volume ratio; max. LA vol., maximum left atrial volume; MBF,
myocardial blood flow; MPR, myocardial perfusion reserve; PEDSR, peak early diastolic strain rate; VO2
max, maximal oxygen consumption.
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−0.01) s−1 for liraglutide and sitagliptin, respectively (Table 2). How-
ever, there was no difference in change between groups (intervention
effect = −0.01 [−0.07, 0.06] s−1). Similarly, there were no between-
group differences in other CMR imaging-derived measures of cardio-
vascular structure and function between baseline and 26 weeks. Mul-
tiple imputations for missing data did not change the interpretation
(Table 2).
3.3 | Effects on cardiometabolic measures
After 26 weeks of treatment there was an intervention effect in
favour of liraglutide for a reduction in HbA1c of −4.57 (−9.10,
−0.37) mmol mol−1 (−0.42 [−0.83, −0.01%]). There was also
greater body weight reduction in the liraglutide arm (mean body
weight and BMI difference −3.88 [−5.74, −2.01] kg [P <0.001],
−1.32 [−2.03, −0.62] kg m−2 [P <0.001], respectively) and a signifi-
cant reduction in the liver function test for alanine transaminase
with liraglutide (−11.27 [−20.17, −2.37] IU−1). There were no
between-group differences in brachial blood pressure (mmHg),
heart rate (min−1) or cardiorespiratory fitness (VO2 max)
(mL kg−1 min−1) (Table 3).
3.4 | Safety
Safety data are summarized in Table S1, with a full list of non-serious
adverse events (split by medication) presented in Table S2. Six par-
ticipants withdrew because of side effects attributable to the study
medication. These were predominantly gastrointestinal in origin,
notably nausea, vomiting and diarrhoea. There were four serious
adverse events reported in the sitagliptin arm, all deemed unrelated
to the medication, and none in the liraglutide arm of the study. There
were no reported severe hypoglycaemic episodes and no partici-
pants required glucose-lowering rescue therapy during the trial.
There were eight reported episodes of minor hypoglycaemia, com-
prised of six individuals (two in liraglutide vs. four in sitagliptin).
4 | DISCUSSION
The LYDIA study shows that short-term use of the GLP-1 receptor
agonist liraglutide did not affect PEDSR compared with the DPP-4
inhibitor sitagliptin, with both groups showing a small decrease over
time. There were no significant between-group differences in any
CMR imaging-measured markers of structure and function.
TABLE 2 Summary of primary and secondary cardiac magnetic resonance (CMR) imaging outcomes
Mean change from baseline (95% CI)
n Liraglutide n Sitagliptin
Intervention effect
(liraglutide minus sitagliptin)
P-value
Primary outcome
PEDSR complete case ITT Circ. (s−1) 28 −0.06 (−0.10, −0.01) 33 −0.05 (−0.10, −0.01) −0.01 (−0.07, 0.06) 0.874
PEDSR IMP Circ. (s−1) 31 −0.07 (−0.12, −0.02) 33 −0.06 (−0.10, −0.01) −0.01 (−0.08, 0.05) 0.707
Secondary outcomes
PEDSR ITT long. (s−1) 28 −0.08 (−0.13, −0.03) 33 −0.04 (−0.08, −0.01) −0.04 (−0.11, 0.03) 0.254
LVGCS (%) 28 0.66 (0.15, 1.17) 33 0.27 (−0.20, 0.73) 0.39 (−0.30, 1.09) 0.274
LVGLS (%) 28 0.33 (−0.35, 1.01) 33 0.43 (−0.19, 1.05) −0.09 (−1.05, 0.85) 0.841
LVEDVI (mL m−2) 28 −0.23 (−2.90, 2.44) 33 −1.50 (−3.93, 0.92) 1.27 (−2.40, 4.94) 0.497
LVEF (%) 28 −0.60 (−2.72, 1.53) 33 1.39 (−0.52, 3.30) −1.98 (−4.90, 0.94) 0.183
LVM (g) 28 0.72 (−3.94, 5.37) 33 −0.43 (−4.59, 3.75) 1.14 (−5.23, 7.50) 0.726
LVMI (g m−2) 28 1.27 (−0.88, 3.42) 33 −0.26 (−2.22, 1.69) 1.54 (−1.41, 4.49) 0.308
LV peak filling rate (mL s−1) 28 10.9 (−18.0, 39.7) 32 −18.7 (−44.9, 7.5) 29.6(−10.2, 69.3) 0.145
LVM/V (g mL−1) 28 0.03 (−0.11, 0.07) 32 0.01 (−0.03, 0.05) 0.02 (−0.04, 0.07) 0.510
Max. LA vol. (mL) 28 −3.82 (−8.88, 1.23) 32 −0.81 (−5.49, 3.85) −3.01 (−10.10, 4.09) 0.406
Global stress MBF (mL min−1 g−1) 25 −0.21 (−0.49, 0.06) 30 −0.15 (−0.40, 0.97) −0.06 (−0.44, 0.32) 0.748
Global rest MBF (mL min−1 g−1) 25 −0.14 (−0.26, −0.02) 30 −0.21 (−0.32, −0.10) 0.07 (−0.09, 0.23) 0.412
MPR 25 −0.09 (−0.46, 0.28) 30 0.19 (−0.15, 0.53) −0.28 (−0.79, 0.24) 0.291
Mean AD (mmHg−1 × 10−3) 24 −0.05 (−0.48, 0.38) 24 0.30 (−0.13, 0.73) −0.35 (−0.98, 0.28) 0.275
Abbreviations: AD, aortic distensibility; CMR, cardiac magnetic resonance imaging measures; LV, left ventricular; LVEDVI, left ventricular end-diastolic
volume index; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVGCS, left ventricular global circumferential strain; LVGLS, left
ventricular global longitudinal strain; LVMI, left ventricular mass index; LVM/V, left ventricular mass/volume ratio; max. LA vol., maximum left atrial
volume; MBF, myocardial blood flow; MPR, myocardial perfusion reserve; PEDSR complete case ITT Circ., peak early diastolic circumferential strain rate
complete case intention-to-treat analysis (primary outcome, primary analysis); PEDSR IMP Circ., peak early diastolic circumferential strain rate multiple
imputation analysis (primary outcome, sensitivity analysis); PEDSR Long., peak early diastolic longitudinal strain rate intention-to-treat analysis.
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Importantly, LYDIA specifically targeted asymptomatic younger
adults with obesity and type 2 diabetes because this group has a signifi-
cant lifetime risk of cardiovascular complications and in many cases evi-
dence of subclinical but probable reversible cardiac dysfunction.27,28
Any observed benefit from early intervention in this group is therefore
likely to be extremely relevant to clinical practice as these agents are
already licenced for use in the glucose-lowering management of adults
with type 2 diabetes.
In this rapidly evolving field, a number of large clinical trials have
reported their findings since the LYDIA study was first designed.
Some of these have advanced our understanding of the cardiovascular
effects of these and other glucose-lowering therapies and help place
our findings in context. Increased hospitalization for heart failure
with the DPP-4 inhibitor saxagliptin in the Savor-Timi 53 trial and a
non-statistically significant increase in the same outcome in the
EXAMINE study of alogliptin provided the original rationale for a
potentially sizeable active comparator differential with liraglutide in
LYDIA.4,11 Subsequent publication of the TECOS (sitagliptin), CAR-
MELINA (linagliptin), ELIXA (lixisenatide), LEADER (liraglutide),
SUSTAIN-6 (semaglutide), EXSEL (exenatide), HARMONY
(albigltuide) and REWIND (dulaglutide) trials indicates that incretin
medications probably have no overall effect on heart failure out-
comes in older (50-60-year-old) people with type 2 diabetes at high
risk of cardiovascular events.12-19 The secondary findings of these
large cardiovascular outcome trials are in part supported by recently
reported echocardiographic data by Margulies et al and Jorsal
et al.8,9 Importantly, these randomized, placebo-controlled studies
have shown that liraglutide seemingly has no beneficial effect on
LVEF, rehospitalization for heart failure or death in patients with
previously documented cardiac disease. Similar results were
observed in a smaller 12-week study of the GLP-1 receptor agonist
albiglutide in patients with New York Heart Association class III
heart failure29 but contradict the only reported CMR imaging
study.20 In that study liraglutide was associated with improved dia-
stolic function, but this was measured using mitral valve-filling char-
acteristics, which are more prone to alteration with changes in filling
pressure, unlike PEDSR.20 A very small reduction in left ventricular
(LV) mass was also shown and this may be primarily because of the
use of placebo as a comparator, rather than our active control with
sitagliptin. We await with interest the results of other CMR imaging
studies, including the saxagliptin on cardiac structure and function
study (SCARF, NCT 02481479), which aims to examine the effects
of this drug in patients without LV dysfunction and will provide addi-
tional information about potential DPP-4 class effects.
Our results are in line with meta-analyses of trial and observational
data showing either little effect on or even a signal for deterioration in
heart failure outcomes in patients with type 2 diabetes treated with
incretin-based therapies.30-35 In this respect our findings are timely in
adding scarce CMR imaging data to the available evidence assessing
the short-term effects of GLP-1 receptor agonists and DPP-4 inhibitors
on indices of cardiac function. This work also adds to our understanding
of the significant improvements seen in mortality and cardiovascular
disease outcomes in recent outcome trials of certain GLP-1 receptor
agonists.
TABLE 3 Summary of secondary cardiometabolic outcomes
Mean change from baseline (95% CI)
Liraglutide Sitagliptin
n n
Intervention effect
(liraglutide minus sitagliptin)
P-value
HbA1c (%) 31 −0.89 (−1.18, −0.60) 33 −0.48 (−0.76, −0.18) −0.42 (−0.83, −0.01)
0.048HbA1c (mmol mol−1) 31 −9.90 (−13.12, −6.67) 33 −5.32 (−8.46, −2.19) −4.57 (−9.10, −0.37)
Weight (kg) 31 −4.51 (−5.84, −3.19) 33 −0.63 (−1.92, 0.66) −3.88 (−5.74, −2.01) <0.001
BMI (kg m−2) 31 −1.60 (−2.10, −1.10) 33 −0.28 (−0.77, 0.20) −1.32 (−2.03, −0.62) <0.001
Systolic BP (mmHg) 31 −8.90 (−12.02, −5.78) 33 −8.73 (−11.77, −5.69) −0.17 (−4.56, 4.22) 0.939
Diastolic BP (mmHg) 31 −5.15 (−7.61, −2.70) 33 −3.88 (−6.27, −1.50) −1.49 (−5.07, 2.09) 0.473
Heart rate (min−1) 31 13.49 (9.57, 17.41) 33 7.96 (4.15, 11.78) 5.53 (−0.06, 11.12) 0.052
Total cholesterol (mmol L−1) 31 0.11 (−0.11, 0.34) 33 −0.23 (−0.45, −0.01) 0.35 (0.02, 0.67) 0.036
LDL-C (mmol L−1) 28 0.21 (0.02, 0.40) 31 −0.09 (−0.27, 0.09) 0.29 (0.03, 0.57) 0.028
HDL-C (mmol L−1) 30 0.03 (−0.02, 0.08) 32 0.01 (−0.04, 0.07) 0.02 (−0.06, 0.10) 0.620
Triglycerides (mmol L−1) 31 −0.32 (−0.57, −0.06) 33 −0.35 (−0.60, −0.10) 0.04 (−0.32, 0.39) 0.833
Alanine transaminase (IU L−1) 31 −4.92 (−11.22, 1.37) 33 6.35 (−0.23, 12.46) −11.27 (−20.17, −2.37) 0.013
eGFR (mL min−1) 31 −0.58 (−2.47, 1.31) 33 −3.02 (−4.85, −1.18) 2.43 (−0.29, 5.16) 0.080
VO2max (mL kg
−1 min−1) 22 0.46 (−0.40, 1.33) 24 −0.47 (−1.30, 0.35) 0.94 (−0.29, 2.17) 0.135
Abbreviations: BP, brachial blood pressure; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein cholesterol;
LDL-C, low density lipoprotein cholesterol; VO2 max, maximal oxygen consumption.
Note: Data adjusted for baseline value along with age, baseline HbA1c and baseline weight. Mean (SD). P in bold indicates statistical significance.
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It has been postulated that liraglutide may mediate anti-
inflammatory and or anti-atherosclerotic effects, which probably take
some time to become clinically apparent. In this situation changes
occurring over months and possibly reflecting comparatively rapid
structural or haemodynamic changes would be improbable with this
pharmacological action. Interestingly, in the LYDIA study there were
no between-group differences in high sensitivity CRP and other pro-
inflammatory biomarkers after 26 weeks (data not shown), although it
should be recognized that the study was not powered to detect
changes in those measures. We also assessed changes in myocardial
perfusion, which would have improved if there was a significant effect
of these treatments on atherosclerosis, which is of particular interest
because GLP-1 receptor agonists have been associated with a reduc-
tion in both myocardial infarction and stroke.18,19 No significant
changes were observed in perfusion but a longer duration of follow-
up may be required, in particular because the reduction of atheroscle-
rotic events with GLP-1 receptor agonist therapy appears slow
compared with the rapid reductions in atherosclerotic episodes and
heart failure hospitalizations with SGLT-2 inhibitors.35-40
Future placebo-controlled studies of longer duration, incorporating
additional measures of inflammation and possibly also including members
of the SGLT-2 inhibitor family may provide additional useful insights.
Following on from the EMPA-REG (empagliflozin), CANVAS, CANVAS-R,
CREDENCE (canagliflozin) and DECLARE-TIMI 58 (dapagliflozin) trials,
there is now considerable interest in the therapeutic potential of SGLT-2
inhibition in heart failure.35-40 The EMPA-Heart study has shown a small
(2.6 g m−2) but significant reduction in LV mass with empagliflozin.40 The
current study failed to show a benefit in LV mass reduction in either arm,
despite marked reductions in blood pressure and a 4.5 kg reduction in
weight with liraglutide.
Absence of a control arm in LYDIA prevents firm conclusions being
drawn about the individual effects of these agents on PEDSR. However,
in the absence of a beneficial effect over sitagliptin, it is important to
consider the secondary glucose- and weight-lowering efficacy of GLP-1
receptor agonist-based treatments in this unique population. Diabetes
management as judged by HbA1c and body weight were improved com-
pared with DPP-4 inhibition and both treatments were well tolerated
with no severe hypoglycaemic episodes when added to preprescribed
oral therapies. These results emphasize the importance of adopting an
individualized approach to diabetes care when considering type 2 diabe-
tes treatments and suggest that early use of weight-sparing or weight-
lowering agents in younger obese patients is an effective option.
This trial does have some important limitations. First, the choice
of an open-label comparator rather than blinded placebo or three-arm
design makes it difficult to estimate individual drug effects compared
with a ‘control’ comprising no additional treatment. However, the pri-
mary endpoint was robustly blinded not only to therapy but also to
whether the scan was baseline or follow-up. No positive effect of
liraglutide on PEDSR or strain was observed compared with sitagliptin
and it can be confidently stated that short-term treatment does not
improve or dramatically worsen diastolic cardiac function in one medi-
cation compared with the other. Although a small worsening in
PEDSR was observed in both intervention groups over time, this
effect was unlikely to be clinically meaningful and the study design
does not allow conclusions to be drawn as to whether this was
because of the study drugs, natural worsening of PEDSR over time, or
a measurement artefact. Second, the study was not designed to
achieve glycaemic equipoise and hence it is not possible to directly
distinguish between glucose-lowering or pleiotropic actions on CMR
imaging outcomes. Third, higher than anticipated attrition and dropout
inevitably affected the certainty (power) of detecting a true difference in
our primary outcome (PEDSR). However, multiple imputations for missing
data did not materially change the results. Fourth, we saw increases in
heart rate and larger reductions in blood pressure than expected, which
may have been overestimated by not including ambulatory monitoring.
Increased chronotropic activity after GLP-1 receptor agonist use in LYDIA
may have had an effect on CMR imaging measurement acquisition.
Also, we did not specifically screen for diabetes-related microangiopathic
complications such as cardiac autonomic neuropathy as the duration of
diabetes was comparatively short. We did exclude participants with evi-
dence of severe coronary artery disease or alternative cardiovascular
structural abnormalities after baseline CMR imaging. Finally, a treatment
exposure time of 26 weeks may not have been sufficient to detect CMR
imaging changes occurring over a longer duration, while the study popula-
tion may not be representative of most people with type 2 diabetes or
those with more advanced cardiac dysfunction.
Comprehensive assessment and detailed phenotyping enabled us
to precisely match treatment groups, examine a range of secondary
outcomes and explore potential novel interactions for future research.
These data come at an important time in the evolution of incretin-
based treatments and add new information about the treatment of
type 2 diabetes. Further CMR imaging studies are needed to explore
the longer term effects of these therapies on cardiac function in people
with type 2 diabetes and should be compared with or in combination
with an SGLT-2 inhibitor.
In conclusion, among young patients with obesity and type 2 dia-
betes, the use of liraglutide resulted in greater weight loss and glucose
control than sitagliptin but did not lead to improvements in subclinical
cardiac dysfunction.
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